Timothy John Norman

USPTO Granted Patents = 21 (Patent Applications = 1)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 5.0

ph-index = 6

Forward Citations = 66(Granted Patents)

Location History:

Buckingshire, GB (2003 - 2009)
Great Missenden, Buckinghamshire, GB (2010)
Great Missenden, GB (2003 - 2011)
Slough Berkshire, GB (2020)
Slough, GB (2011 - 2023)
Berkshire, GB (2024)

Company Filing History:

5. 1 out of 832,680

Other

patents

Years Active: 2003-2025

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12410161 - Tetrahydrobenzo-quinoline sulfonamides derivative compounds (2025-09-09),

2. 12018021 - Thiophene derivatives for the treatment of disorders caused by IgE (2024-06-25),

3. 11674967 - Method of identifying potential inhibitors of APO TNFα trimers (2023-06-13),

4. 11448655 - Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors (2022-09-20),

5. 10883996 - Methods of identifying signaling modulators of the trimeric TNFa (2021-01-05),

6. 10842884 - Endosomolytic agents for gene therapy (2020-11-24),

7. 10775385 - Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers (2020-09-15),

8. 10705094 - TNF receptor signaling modulator assay (2020-07-07),

9. 10287299 - Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity (2019-05-14),

10. 9550737 - TNF -α modulating benzimidazoles (2017-01-24),

11. 8129505 - Comb polymers (2012-03-06),

12. 8053564 - Cross-linked antibodies (2011-11-08),

13. 7910618 - Albumin-binding conjugates comprising a fatty acid and PEG (2011-03-22),

14. 7736635 - Branched molecular scaffolds for linking polymer residues to biologically active moieties (2010-06-15),

15. 7718157 - Targeted lipid particles (2010-05-18),

Title: Innovations of Timothy John Norman: A Pioneer in Pharmacological Advancements

Introduction: Timothy John Norman, based in Slough, Great Britain, is an accomplished inventor with a remarkable portfolio of 19 patents. His work primarily focuses on developments in pharmacology, targeting disorders influenced by immunological responses and inflammatory processes.

Latest Patents: Among his latest innovations, Timothy has developed thiophene derivatives aimed at treating disorders caused by IgE. These compounds, including pharmaceutically acceptable salts, offer potential solutions for conditions such as allergies and type 1 hypersensitivity. Additionally, he has disclosed a method for identifying potential inhibitors of APO TNFα trimers. This new trimeric TNFα structure displays distorted symmetry and binds to the TNFR1 receptor, potentially offering therapeutic avenues for diseases linked to the soluble TNFα/TNFR1 interaction, thereby minimizing risks associated with membrane-bound TNFα signaling.

Career Highlights: Throughout his career, Timothy has made significant contributions to the field as a researcher and inventor. He has worked with notable companies, including UCB Biopharma and Celltech R&D Limited, where he applied his expertise to deepen the understanding and develop novel treatments for complex biological conditions.

Collaborations: Timothy's collaborative efforts with renowned colleagues, such as John Robert Porter and Boris Kroeplien, have enhanced the scope of his inventions. These partnerships have fostered innovative approaches in therapeutic research, reflecting the value of teamwork in scientific advancements.

Conclusion: Timothy John Norman exemplifies the spirit of innovation in the pharmaceutical industry. With his extensive portfolio of patents and collaborations, he continues to push the boundaries of medical science, offering new hope for the treatment of various disorders. His ongoing work remains pivotal in understanding complex immunological responses and developing targeted therapies.

This text is generated by artificial intelligence and may not be accurate.